SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 7th, 2018 • Compugen LTD • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this "Agreement") is dated as of October 10, 2018, between Compugen Ltd., a corporation organized under the laws of the State of Israel (the "Company"), and Bristol-Myers Squibb Company (“Purchaser”), a Delaware corporation.
MASTER CLINICAL TRIAL COLLABORATION AGREEMENTTrial Collaboration Agreement • November 7th, 2018 • Compugen LTD • Biological products, (no disgnostic substances) • New York
The Parties desire to agree on the following terms in order to develop innovative medicines as promptly as reasonably practicable, to avoid intellectual property and other conflicts with Third Parties in related subject matter transactions, and to better ensure that each Party focuses its efforts on the development of an appropriate Combined Therapy Clinical Trial and that the agreed-upon Combined Therapy Clinical Trial proceed in an effective, cost-efficient and timely manner:
